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Abstract: The issue of drug chirality is attracting increasing attention among the scientific commu-
nity. The phenomenon of chirality has been overlooked in environmental research (environmental oc-
currence, fate and toxicity) despite the great impact that chiral pharmacologically active compounds 
(cPACs) can provoke on ecosystems. The aim of this paper is to introduce the topic of chirality and its 
implications in environmental contamination. Special attention has been paid to the most recent ad-
vances in chiral analysis based on liquid chromatography coupled with mass spectrometry and the 
most popular protein based chiral stationary phases. Several groups of cPACs of environmental rele-
vance, such as illicit drugs, human and veterinary medicines were discussed. The increase in the num-
ber of papers published in the area of chiral environmental analysis indicates that researchers are actively pursuing new 
opportunities to provide better understanding of environmental impacts resulting from the enantiomerism of cPACs. 
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1. INTRODUCTION TO DRUG CHIRALITY AND ITS 
ENVIRONMENTAL RELEVANCE 
The issue of drug chirality is now a major topic with an 
impact in various fields such as agriculture, pharmaceutical 
and chemical industries. Molecules consisting of the same 
number and types of atoms or groups, but differing only in 
their spatial arrangement, are called stereoisomers. If two 
stereoisomers are mirror images of each other then they are 
called enantiomers. Enantiomers have identical physical and 
chemical properties except for the fact that they rotate polar-
ized light in opposite direction (phenomenon called optical 
activity) due to the presence of a chiral center originated by 
planes, axis or centers of asymmetry (e.g. asymmetric car-
bon). Enantiomers respond identically to an achiral environ-
ment. However, they can interact differently with other 
chiral molecules, such as receptors and enzymes which are at 
molecular level homochiral. As a result, enantiomers of the 
same chiral compound can differ in their biological proper-
ties such as distribution, metabolism and excretion.  
Chiral pharmacologically active compounds (cPACs) 
(Fig. (1)) can undergo stereoselective disposition in the 
body, which can be affected by disease, ethnic difference, 
sex, age and lifestyle as well as co-administration of other 
drugs [1]. Thus, one enantiomer usually is favoured over the 
other. Additionally, during metabolism cPACs can show 
chiral inversion. Chiral inversion can be unidirectional (e.g. 
in 2- arylpropionic acids (profens) only an inactive R-
enantiomer can undergo inversion into an active  
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S-enantiomer) orbidirectional (racemization, e.g. in benzodi-
azepines) [1]. 
Enantiomers often exhibit different pharmacokinetics and 
pharmacodynamics that can result in stereoselective toxicity. 
Unfortunately, despite the fact that only one enantiomer is 
usually responsible for the desired activity whereas the other 
may be inactive or responsible for adverse effects; many 
drugs have been commercialized as ‘racemates’ or ‘racemic 
mixtures’. To date, most studies do not explicitly account for 
individual enantiomers despite the growing evidence for 
enantiomer-selective toxicity of cPACs towards aquatic or-
ganisms as in the case of fluoxetine and propranolol [2, 3].  
According to current legislation, a new veterinary or hu-
man medicine has to be subjected to an environmental risk 
assessment (ERA) to evaluate the potential risk of an active 
compound to the environment, based on protocols performed 
according to the current European Medicines Agency guide-
lines. They specify two phases: in Phase I an assessment of 
the potential extent of exposure to the environment takes 
place and if the so-called ‘action limits’ are exceeded then 
the drug will be subject to a risk assessment in Phase II. 
However in none of the phases chirality is considered. As a 
consequence, current approaches utilized in ERA might lead 
to erroneous and misleading results. It is therefore of the 
highest importance that more comprehensive ecotoxicity 
studies taking into account stereochemistry of cPACs, are be 
required for the approval of any new chiral drug by regula-
tory authorities. 
The need to develop enantioselective methods has 
arisen for the quantitative assessment of the contribution of 
each enantiomer and to determine the enantiomeric excess 
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[4]. In order to discriminate chiral compounds, the analyte 
of interest should be added into a chiral environment (e.g., 
a chiral derivatizing agent or a chiral stationary phase 
(CSP)) which enables differentiation of enantiomers 
through the formation of distinguishable diastereomers 
with distinct physico-chemical properties via multipoint 
interactions. The chiral recognition mechanism is usually 
explained by the “three point interaction model”. Here a 
minimum of three simultaneous interactions being stereo-
chemically dependent, are required [5]. In chiral analysis 
two approaches can be used: so called direct and indirect 
methods. Direct enantioseparation methods are based on 
interactions with a chiral selector (either bound to the sta-
tionary phase of the column or as chiral additives in the 
mobile phase) resulting in the temporary formation of di-
astereomers. In the indirect enantioseparations, analytes are 
derivatized with enantiomerically pure chiral derivatizing 
agents resulting in the formation of a pair of diastereomers, 
which can be afterwards separated in an achiral environ-
ment. As an example, enantioseparation of 2-arylpropionic 
acids has been achieved with direct methods using cyclo-
dextrins bound to the stationary phase [6, 7] or as mobile 
phase additives [8, 9], and with indirect methods by the 
derivatization of the R- and S-enantiomers to amide di-
astereomers using (R)-1-phenylethylamine [10]. 
The relative proportion of a pair of enantiomers is com-
monly expressed in terms of the enantiomeric fraction (EF), 
which equals 0.5in the case of a racemic compound and 1.0 
or 0.0 in the case of an enantiomerically pure compound. 
The accurate determination of EF can provide insights of the 
compound’s history, as well as pointing to the nature and 
sources of environmental pollution [10]. 
The importance of enantiomeric analysis of cPACs in the 
environment is mainly linked to four research are as that 
include:  
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(i) Fate of cPACs during wastewater treatment. After the 
administration of cPACs their enantiomeric composition can 
be altered owing to human or animal metabolism. Once they 
reach wastewater treatment plants (WWTPs) they are sub-
jected to biotic processes that lead to further changes in their 
enantiomeric composition. Accordingly, it may be expected 
that their EF in untreated sewage would differ from the one 
observed in treated effluents. It is necessary to distinguish 
between untreated and treated sewage because the effluent 
might be enriched with one of the enantiomers and current 
risk assessment does not consider it. Only a few studies have 
reported these changes in EF in wastewater samples [1, 11-
21];  
(ii) Wastewater-based epidemiology (WBE). This is an 
innovative approach that enables retrieving epidemiological 
information from wastewater via the analysis of human 
metabolic excretion products called biomarkers. It is for ex-
ample employed to estimate illegal drug use within a com-
munity [22]. Enantiomeric profiling can supplement WBE 
data with valuable information on abuse trends and potency 
of chiral drugs and can also help with distinguishing between 
legal and illicit use of drugs as well as providing an indica-
tion of actual consumption as opposed to direct disposal of 
unused drugs [23];  
(iii) cPACs as chemical markers of water contamination 
with wastewater. Several studies reported change in EF of 
chiral contaminants during biological wastewater treatment, 
which provides information about their history and makes 
possible to distinguish between untreated effluents and 
treated effluents discharged from WWTPs. Therefore some 
cPACs that undergo consistent and significant measurable 
EF changes during wastewater treatment could serve as ef-
fective indicators of human sewage contamination in water 
courses (e.g. propranolol) [11];  
(iv) ERA and fate in the environment. Current ERA is of-
ten inaccurate because it evaluates environmental impacts 
based on a whole drug and does not account for individual 
enantiomers [24-29]. This might lead to inaccurate estima-
tion of environmental fate and toxicity and might result in 
misleading conclusions regarding cPAC in question. As al-
ready mentioned, biologically mediated processes are of-
tenenantioselective and may change the EF of the chiral 
drug, whereas abiotic processes (e.g. sorption, photochemi-
cal transformation, air-water, and soil-water exchange) are 
generally notenantioselective. This phenomenon makes 
cPACs (those undergoing enantioselective metabolism) use-
ful biotransformation markers. 
2. CHIRAL LIQUID CHROMATOGRAPHY COU-
PLED WITH TANDEM MASS SPECTROMETRY FOR 
ENANTIOMERIC PROFILING OF CHIRAL HUMAN 
PHARMACOLOGICALLY ACTIVE COMPOUNDS 
AND ITS RECENT ADVANCES 
To date, the majority of work undertaken in this field of 
research has focused on whole PAC concentration. This typi-
cally involves reverse phased chromatography which can 
analyse a large number of PACs (>50) simultaneously [30-
32]. However, there is increased knowledge of enantiomer 
specific toxicity towards some aquatic species [2, 3]. This 
has driven research of PACs in environmental waters at the 
enantiomeric level. Traditionally though, methods capable of 
enantiomeric separation have been limited to use in quality 
control purposes for the pharmaceutical industry. These typi-
cally use ultra-violet detection with mobile phases not com-
patible with mass spectrometry (MS) [33]. However, com-
patibility with MS is essential as the high sensitivity and 
selectivity of tandem mass spectrometry is needed for envi-
ronmental analysis. Several liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) methods have now been 
developed and applied to the chiral analysis of several hu-
man PAC sub-groups including beta-blockers, anti-
depressants and profens (2-arylpropionic acids) in environ-
mental matrices (Table 1). 
Table 1. Validated chiral liquid chromatography methods coupled with tandem mass spectrometry for enantiomeric profiling of 














mephedrone, MDMA, MDA,  






ter (100 mL) 
Grab Filtration (0.7 
m), Oasis 
HLB SPE 
Chiral-CBH column (100 
x 2 mm, 5 m particle 
size). 85: 15 H2O: MeOH 





Ibuprofen, naproxen, ketoprofen, 
chloramphenicol, ifosfamide, 10,11 
dihydrocarbamazepine, fexofenadine, 
3-n-dichloroethylifosfamide, dihy-
droketoprofen, tetramisole, aminorex, 
praziquantel 
Effluent wastewa-
ter (250 mL), river 
water (500 mL) 
Grab Filtration (0.7 
m), Oasis 
HLB SPE and 
Oasis MCX 
AGP (100 x 2 mm, 5 m
particle size). 99: 1 H2O
with 10 mMNH4OAc: 
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fluoxetine, salbutamol, sotalol, cita-
lopram 
Influent wastewa-
ter (50 mL), 
effluent wastewa-











Chirobiotic V (250 x 4.6
mm, 5 m particle size). 
MeOH with 4 mM 
NH4OAc, 0.005 % formic
acid. 
Chiral-CBH column (100 x
2 mm, 5 m particle size).
90: 10 H2O: 2-propanol with











Ibuprofen, ketoprofen, naproxen Influent wastewa-
ter (72.2 mL), 
effluent wastewa-






x 4.6 mm, 5 m particle 
size). 90:10 tetrahydro-







ne, alprenolol, bisoprolol, metoprolol,
propranolol, salbutamol 
Effluent wastewa-





Chirobiotic V (150 x 2.1
mm, 5 m particle size). 
92.5: 7.5 H2O with 10 mM




Betaxolol, propranolol, ibuprofen, 
pindolol, fluoxetine, salbutamol, 
sotalol, timolol, carazolol, clen-
buterol, metoprolol, atenolol 
Influent wastewa-
ter (100 mL), 
effluent wastewa-
ter (100 mL), river








Chirobiotic V (250 x 4.6
mm, 5 m particle size). 
MeOH with 4 mM 




0.2-28 ng L-1 
influent wastewa-
ter, 0.2-28 ng L-1
effluent wastewa-




MDMA, propranolol, atenolol, me-
toprolol, venlafaxine, fluoxetine 
Effluent wastewa-
ter (100 mL), river




Chirobiotic V (250 x 4.6
mm, 5 m particle size). 
MeOH with 4 mM 
NH4OAc, 0.005 % formic
acid. Chiral-CBH column
(100 x 2 mm, 5 m parti-
cle size). 90: 10 H2O: 2-
propanol with 1 mM 






0.3-39 ng L-1 
river water 
[16]
Fluoxetine, norfluoxetine Influent wastewa-
ter (200 mL), 
effluent wastewa-
ter (500 mL) 
Grab pH adjusted to
4, Evolute 
CX-50 SPE 
AGP (100 x 2 mm, 5 m
particle size). 97: 3 H2O








MDEA, MDMA, MDA,  
Influent wastewa-
ter (100 mL), 
effluent wastewa-





x 2 mm, 5 m particle 
size). 90: 10 H2O: 2-
propanol with 1 mM 









Atenolol, metoprolol, pindolol, 
propranolol, sotalol, citalopram, 
salbutamol 
Influent wastewa-
ter (100 mL), 
effluent wastewa-




Chirobiotic V (250 x 4.6
mm, 5 m particle size). 
90: 10 MeOH: H2O with
20 mM NH4OAc, 0.1 % 









Atenolol, metoprolol, propranolol Influent wastewa-
ter (100 mL), 
effluent wastewa-




Chirobiotic V (250 x 4.6
mm, 5 m particle size). 
90: 10MeOH: H2O with 
0.1 % triethyl ammonium
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2.1. Beta-blockers 
The most well studied group of compounds at the enanti-
omeric level is beta-blockers such as atenolol, metoprolol 
and propranolol (Table 1). Methods in the literature report 
the use of Chirobiotic V columns which contain an antibiotic 
based stationary phase. Chirobiotic V has an isoelectric point 
(pI) of 7.2 therefore under typical mobile phase conditions 
(pH 3.5-7.5) the ionisable groups of this CSP will be posi-
tively charged. This CSP is compatible with polar organic 
mobile phases (e.g., methanol) which is advantageous for 
environmental analysis due to ease of coupling to MS as well 
as the excellent sensitivity achieved. Ammonium acetate is 
often added as a mobile phase buffer as it improves ionisa-
tion as well as increasing the separation of enantiomers dur-
ing chromatography [34]. Methods tend to operate at flow 
rates of 0.1 ml min
-1
 and run times of ~60 min to achieve 
adequate enantiomeric separation. Application of these 
methods have successfully shown that several beta-blockers 
(atenolol, metoprolol and propranolol) undergo stereo-
selective biodegradation during wastewater treatment [11, 
15, 18, 34, 35]. This leads to the enrichment of one enanti-
omer in final effluent discharges. This information is missed 
by commonly used achiral methods, yet it is essential for 
establishing accurate ERA. Chiral analysis has also success-
fully indicated direct disposal of atenolol. A high estimated 
population usage coincided with a racemic EF suggesting 
metabolism by the human body had not occurred [35]. 
2.2. Anti-depressants 
Several analytical methods reported in the literature (Ta-
ble 1) successfully separate enantiomers of the anti-
depressant fluoxetine and its active metabolite norfluoxetine 
[36-38]. This is underpinned by the enantiomer dependent 
toxicity of fluoxetine to various aquatic indicator species [3]. 
Again, the Chirobiotic V column is suitable for enantiomer 
separation here [37]. Successful separation of fluoxetine is 
also achievable by macrocyclic glycoprotein based columns 
such as CBH (cellobiohydrolase I) and AGP (1-acid glyco-
protein) [36] columns. Similarly, venlafaxine has been sepa-
rated by both Chirobiotic V (Fig. 2) and CBH [13, 38-40] 
columns [16, 41]. A direct comparison of two different 
methods which can separate venlafaxine enantiomers at simi-
lar retention times (Rt) showed the Chirobiotic V method to 
be ~15 times more sensitive than the CBH method [16]. To 
demonstrate, venlafaxine method quantitation limits (MQLs) 
in river water were 8.1 and 7.9 ngL
-1
for the S-(+)- and R-(-)-
enantiomers using the Chirobiotic V method. For the CBH 
method, MQLs were 51.7 and 47.9 ngL
-1
, respectively. This 
is likely to be caused by a lower MS signal from an aqueous 
based mobile phase (CBH method) in comparison to an or-
ganic one (Chirobiotic V method) [16]. Nevertheless, CBH 
has shown to be beneficial for achieving separation of a 
larger number of chemical groups including several illicit 
drugs and their metabolites [38]. 
2.3. Profens 
cPACs are often prepared and dispensed as racemic mix-
tures. Interesting though, some cPACs, such as naproxen, are 
prescribed as a single enantiomer because only the S enanti-
omer exerts a beneficial therapeutic response in the human 
body (the R enantiomer is suspected to be a liver toxin) [42]. 
Chiral inversion has been observed for ibuprofen and 
naproxen during wastewater treatment [10, 21]. This phe-
nomenon can be used as a diagnostic tool to help distinguish 
between treated and untreated sources of contamination in the 
environment [21]. Due to chiral inversion, it is also necessary 
to develop chiral methods for cPACs which are dispensed as 
single enantiomers. At present, there is a lack of LC methods 
suitable for the enantiomeric determination of profens (ibupro-
fen, ketoprofen, naproxen). Caballo et al. [20] successfully 
achieved separation using (R)-1-naphthylglycine 3,5-
dinitrobenzoic acid as CSP and a mobile phase consisting of 
90% tetrahydrofuran and 10% ammonium acetate (50mM) in 
methanol (Table 1). MQLs in influent and effluent wastewa-
ters were ~1 ngL
-1
. Also, other study used an AGP column for 
their separation with a mobile phase mostly aqueous (10mM 
ammonium acetate/acetonitrile, 99:1, v/v). This achieved 
MQLs on the range of low ng L
-1 
[43]. Gas chromatography-
Fig. (2). Mass chromatograms of chiral human pharmaceutical sextracted from final effluent and analysed using Chirobiotic V. 
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tandem mass spectrometry (GC-MS/MS) methods also exist 
but derivatization is required prior to analysis [10]. 
2.4. Non-targeted Analysis 
Chiral chromatography can also be applied (with suitable 
MS) for the identification of unknown compounds. Most 
methods reported in the literature use triple quadrupole tan-
dem mass spectrometers due to their high sensitivity (Table 1). 
Despite being excellent for quantitative determinations, they 
cannot perform non-targeted analysis. However, the increasing 
sensitivity of high resolution mass spectrometers enable quan-
titative (targeted screening) and qualitative (non-targeted 
screening) determinations simultaneously. To demonstrate, 
Bagnall et al. [16] successfully used quadrupole time-of-flight 
mass spectrometry (QTOF-MS) to identify and confirm sev-
eral cPACs at the enantiomeric level in final effluent and river 
water extracts whilst using Chirobiotic V column. Coupling 
chiral chromatography with high resolution MS could there-
fore be used to help identify cPACs and estimate their enanti-
omeric distribution, as well as to identify transformation pat-
terns. It is worth emphasizing here that transformation by-
products can be also chiral. At present this is an area where 
little/no work has been conducted. This is mainly a result of 
poor understanding of the mechanisms of chiral separation 
using various stationary phases and the influence of mobile 
phase composition. For this concept to be successful, a greater 
understanding of chiral separations and modelling the likeli-
hood of achieving separation of cPACs which possess a broad 
range of physico-chemical properties is needed. Furthermore, 
the development of chiral stationary materials capable of 
multi-dimensional chiral recognition of several structurally 
diverse chemical targets is required for successful application 
of high resolution MS in non-targeted analysis of cPACs. 
3. CHIRAL LIQUID CHROMATOGRAPHY COU-
PLED WITH TANDEM MASS SPECTROMETRY FOR 
ENANTIOMERIC PROFILING OF CHIRAL VET-
ERINARY MEDICINES 
World production and consumption of PACs intended for 
veterinary applications has been steadily increasing at an 
alarming rate during the last decades. These compounds are 
widely used to protect animal health, prevent economic loss, 
and promote animal growth, ensuring a safe food supply [44]. 
Despite their benefits, the potential adverse impacts on biota 
and human health has become a matter of increasing concern 
due to their continuous release into the environment, either 
directly from aquaculture, by grazing animals, or indirectly 
during manure spreading [45]. The presence of significant 
amounts of residual PACs and their metabolites have been 
reported in different environmental compartments (wastewater, 
surface and ground waters, river sediments and soils) [46-55]. 
Although there is a general move within the European 
Union towards reducing veterinary medicine use, the use of 
drugs to maintain animal health and welfare remains a neces-
sity. Of the various PACs commonly used in veterinary 
medicine, special attention has been paid to antibiotics due to 
their high detection frequency in the environment and their 
potential health risk. Antibiotics may cause a direct toxic 
effect on microflora and microfauna [56], an emergence and 
spread of resistant bacteria [57] that would affect humans or 
other animals/organisms [58-60] or even multi-drug resistant 
pathogen strains, such as in the case of methicillin-resistant 
Staphylococcus aureus, and carbapenem-resistant Entero-
bacteriuaceae [61]. As evidence, the use of antibiotics as 
growth promoters in animal husbandry in the European Un-
ion has been banned since 2006 [62]. However, although 
monensin sodium or salinomycin sodium were banned for 
fattening in cattle and pigs, respectively, they are allowed for 
chicken and turkeys fattening in the United Kingdom [63]. 
To prevent the risks to human health and the environment 
the approval and use of veterinary medicines in the European 
Union are to a large extent regulated by the European Direc-
tive 2001/82/EC (amended by Directive 2004/28/EC) and by 
the European Regulation 726/2004/EC. However, none of 
the proposed guidelines consider key phenomena character-
istic to veterinary medicines. These are: metabo-
lism/excretion in target animals or the degradation processes 
that take place during manure storage or after the manure is 
applied onto the soils, as well as stereoselective environ-
mental fate and ecotoxicological effects. 
In order to achieve on above, there is a need for reliable 
multiresidue analytical methods, both for screening and con-
firmation purposes of veterinary medicines in the environ-
ment. Most papers published present procedures for active 
compounds in drug formulations, in various biological sam-
ples or in food of animal origin, but only a few have been fo-
cused in solid and aqueous environmental matrices. Most of 
the current available methods involve the use of LC-MS/MS 
[45, 53, 64-67]. Also, they have been focused primarily on 
therapeutic groups over which concern has been raised. Fur-
thermore, there are no published methods, which allow for 
separation of chiral veterinary medicines at enantiomeric level.  
Existing enantioselective multiclass analytical methods 
are focused on illicit drugs in environmental matrices, beta-
blockers, anti-inflammatory drugs and antidepressants [16, 
23, 34, 35, 37, 68]. Unfortunately, there are no published 
methods allowing for chiral analysis of veterinary medicines 
and their biotransformation by-products. Recently developed 
by Camacho-Muñoz and Kasprzyk-Hordern, [43] multi-
residue cLC-MS/MS method enabled simultaneous analysis 
of several veterinary and human cPACs with successful 
enantioseparation of chloramphenicol, ifosfamide and its 
major metabolite (3-N-dechloroethylifosfamide), 10,11-
dihydro-10-hydroxycarbamazepine (a chiral metabolite of 
carbamazepine), fexofenadine, ibuprofen, naproxen, tetrami-
sole and its metabolite aminorex and partial resolution of 
praziquantel, ketoprofen and its metabolite dihydroketopro-
fen (Fig. 3). Due to the variety of veterinary medicines used, 
appropriate methods that cover several therapeutic groups 
are required to evaluate the potential threat to aquatic and 
terrestrial environment. 
4. ENANTIOMERIC PROFILING OF ILLICIT DRUGS 
IN THE ENVIRONMENT WITH CHIRAL CHROMA-
TOGRAPHY AND TANDEM MASS SPECTROME-
TRY USING PROTEIN-BASED CHIRAL STATION-
ARY PHASES 
Macromolecular stationary phases are the main group of 
chiral selectors used in chiral LC environmental analysis of 
drugs [33]. The interest in these protein based selectors 
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emerged because of the chiral distinction capability of en-
zymes and plasma proteins, natural chiral pool of selectors 
[69]. The most important chiral selectors belonging to this 
group are based on human and bovine serum albumin (HSA 
and BSA, respectively), glycoproteins such as AGP and 
crude ovomucoid (OVM)), enzymes (e.g., CBH) and amy-
lose and cellulose based stationary materials. Amongst them, 
acidic chiral compounds are preferably resolved in HSA col-
umns, basic chiral compounds are resolved in CBH columns 
while the broadest enantiomer separation capabilities are pro-
vided by AGP columns [69]. Since many illicit drugs are ba-
sic, CBH and AGP stationary materials are the most widely 
used for the environmental chiral analysis of drugs of abuse. 
CBH column has a cellobiohydrolase enzyme immobi-
lized on to spherical 5 m silica particles as chiral selector 
with apIof 3.9. According to Henriksson et al. [70], three 
main active chiral-recognition areas are defined in the col-
umn: a catalytically active core, a connecting area and a cel-
lobiohydrolase domain with 36 aminoacids forming two di-
sulphide-bridged loops. The catalytically active core contains 
the dominating chiral binding site, whilst the cellulose one 
has the other enantioselective site [71]. Developed by Her-
mansson [72], AGP consists of a single peptide chain with 
181 aminoacids and five heteropolysaccaride units, contain-
ing 14 residues of sialic acid. Due to the presence of this 
acidic component, AGP has a pI of 2.7. Sugar moieties are 
also present [72]. As the tertiary structure is missing, little 
information is available on the chiral recognition sites and 
mechanism of AGP, even if it is known that hydrophobic, 
electrostatic and hydrogen bonding interactions play a key 
role in retention and enantioselectivity [73]. Factors, such as 
temperature, pH and mobile phase composition, can influ-
ence chiral recognition on these CSPs. Also, they are particu-
larly sensitive to these factors, with denaturing a very real 
possibility [74]. Hence, both pH and mobile phase composi-
tion are key parameters to achieve enantioselectivity of tar-
get compounds. Mobile phase pH affects the ionization of 
both solutes and CSPs. Both columns are positively charged 
at pH<pI and negatively charged when pH>pI, so raising the 
mobile phase pH within the recommended range (pH range: 
3-7 and 4-7 for CBH and AGP, respectively) increases the 
negative charges of the CSP, thus determining ionic bonds 
between the CSP and the positively charged solute (i.e. 
amine). As a consequence, higher Rt and an increase of 
enantioselectivity are expected. Hydrophobic interactions 
and hydrogen bonding can be influenced by mobile phases 
containing different nature and percentage (<20%) of or-
ganic modifiers and ionic strength. The most frequently used 
uncharged organic modifiers are methanol, acetonitrile and 
isopropanol. Depending on their nature (i.e. methanol has 
lower elution strength than isopropranol) and their content 
(i.e., lower percentages lead to higher Rt in the case of 
amines) different Rt and enantioselectivities will be ob-
served. Furthermore, the presence of buffers in mobile 
phases can ionise the analytes and alter their interactions 
with the CSP at molecular level. The most used buffers in 
MS methods are ammonium acetate/formate due to their 
compatibility with electrospray ionization (ESI) interfaces in 
MS [75]. 
So far, in environmental analysis, chiral methods have 
been used as complementary tools for the investigation of 
just a few specific chiral compounds (as CSPs were chosen 
Fig. (3). LC-MS/MS chromatograms using an AGP column for chiral human pharmaceuticals, veterinary medicines and their metabolites in 
a standard solution of 600 g L
-1 
of each racemic mixture. 
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on the basis of specific enantiomeric resolution) alongside 
non-chiral multi-residue methods utilizing C18 stationary 
materials [15, 16]. This required an ad hoc sample prepara-
tion, which meant a higher quantity of sample, more time 
consuming and more effective cost analysis. A recently de-
veloped multi-residue method combined chiral recognition 
capability of the CBH-based stationary materials with multi-
residue separation potential of the C18-based materials [38]. 
It enabled the detection and quantification of all targeted 
(both chiral and non-chiral) human biomarkers in wastewater 
along with satisfactory enantiomeric separations of 
18analytesand a unique single sample preparation step. 
In order to study the enantiomeric profiling of illicit 
drugs in the environment and in wastewater, some precau-
tions are required during the sample collection and prepara-
tion. Indeed, an incorrect assessment of the relative concen-
tration of enantiomers might occur at this stage due to the 
enantioselective microbial metabolic degradation of target 
analytes [76]. In order to reduce enantioselective degrada-
tion, a correct storage protocol is highly recommended. To 
minimize microbial activity samples must be kept at low 
temperatures (preferentially frozen) during transport. A con-
troversial question is about the acidification of the sample 
and the addition of sodium azide to eliminatemicrobial activ-
ity as the matrix might be subjected to modification [33]. 
ESI is the most used interface in MS for environmental 
analysis. However this interface can be subject to significant 
signal suppression. Matrix effects can also have negative 
effects on chiral recognition when using chiral LC-MS(ESI) 
[33]. As a consequence, an adequate step to concentrate and 
clean-up the sample, usually carried out through solid phase 
extraction (SPE) is important. The choice of the SPE sorbent 
is key to achieve good recoveries and to maintain chiral rec-
ognition in selected chiral stationary materials. In fact, in the 
case of amphetamines, the specific sorbent to extract basic 
drugs, a mixed-mode cation exchange cartridge (Oasis 
MCX), was discarded because the use of methanol modified 
with ammonium hydroxide as an eluting agent resulted in a 
loss of chiral recognition of amphetamines in the CBH col-
umn [68]. 
A limited number of papers on enantiomeric profiling of 
amphetamines in wastewater and in the environment have 
recently been published. A chiral CBH column (100 x 2mm, 
5m) was used to perform environmental chiral analysis of 
amphetamine-like compounds [77]. In raw wastewater, R-(-
)-3,4-methylenedioxymethamphetamine (R-(-)-MDMA) was 
predominant in respect to the S-(+)-MDMA due to stereose-
lective human metabolism. EF value increased from 0.68 in 
raw wastewater to 0.78 (indicating enrichment of MDMA 
with R-(-)-enantiomer) in treated wastewater due to the 
treatment of wastewater possibly due to stereoselective mi-
crobial metabolic processes. Enantioselective degradation 
was also observed for amphetamine, leading to an enrich-
ment of R-(-)-enantiomer. In the case of ephedrine, the natu-
ral 1R,2S-(-)-enantiomer was detected in raw wastewater, 
whilst the synthetic 1S,2R-(+)-enantiomer was found in 
treated wastewater, showing perhaps a chiral inversion proc-
ess. Receiving waters were also enriched with R-(-)-
enantiomers of amphetamine and MDMA, and 1S,2R-(+)-
ephedrine. Microcosm experiment evaluated with the CBH 
column under isocratic conditions (1mM ammonium ace-
tate/isopropanol 9:1) proved that stereoselective microbial 
metabolic processes lead to enrichment of amphetamine with 
R-(-)-enantiomer [78]. The enantiomeric composition of 3,4-
methylenedioxyamphetamine (MDA)was found to change 
during the treatment of wastewater. Indeed, EF of 0.28-
0.30in raw wastewater (indicating a prevalence of S-(+)-
enantiomer) increased to EF=0.38-0.40 in wastewater efflu-
ent and further to EF=0.56-0.58 in surface waters, indicating 
an enrichment of MDA with R-(-)-enantiomer. This phe-
nomenon was observed due to preferential microbial metabo-
lism of S-(+)-MDA [15].  
The investigation of illicit drugs at enantiomeric level in 
environmental samples is principally performed to under-
stand fate of chiral drugs during wastewater treatment and in 
the environment. It was also proven to be valuable in WBE 
in differentiating between drug consumption and direct dis-
posal of unused drugs, as well as in verifying the origin of a 
drug residue. Indeed an application of chiral analysis of il-
licit drugs in WBE is an attractive one. Originally imple-
mented by Zuccato et al. [79] to estimate drug use in studied 
communities, the WBE concept enables retrieving epidemi-
ological information from wastewater via the analysis of 
human metabolic excretion products called biomarkers. It 
consists of several stages: (i) the measurement of the levels 
of illicit drugs and their metabolites in wastewater, (ii) back-
calculation of the mass loads of the parent drugs associated 
with the investigated population, (iii) and estimation of the 
consumption of drugs in g day
-1
, based on drug metabolisms 
and excretion patterns. The potential of WBE is extraordi-
nary and is currently considered as complementary to other 
more traditional epidemiological tools. WBE offers several 
advantages when compared to other traditional epidemiol-
ogical approaches such as population surveys. These are: (i) 
near real-time profiling of community health and lifestyle, 
which is of key importance in for example tracking the 
emerging trends of new synthetic drug abuse and in verifying 
changes in usage patterns of “classic” drugs of abuse; and 
(ii) to give estimates with the possibility to perform retro-
spective analysis with low-cost studies [80]. 
WBE has been also employed to evaluate the commu-
nity-wide use patterns of illicit drugs such as cocaine and its 
metabolites, amphetamine, opiates and cannabis [81-89]. 
Temporal and spatial trends were initially studied in19 Euro-
pean cities [90] and then in23 European cities [22]. All these 
studies utilized achiral methods. Only a few papers reported 
and correlated the enantiomeric composition of illicit drugs 
found in wastewater to official statistics. Kasprzyk-Hordern 
and Baker [15] reported that amphetamine quantified in 
wastewater was predominantly of illicit origin. This is be-
cause amphetamine was enriched with R-(-)-enantiomer in 
wastewater (only S-(+)-amphetamine, is prescribed in the 
UK). They also found that the presence of MDA in raw 
wastewater (which was enriched with S-(+)-enantiomer) was 
associated with metabolism of MDMA rather than consump-
tion of MDA. Usage patterns of chiral illicit drugs were also 
studied in the Valencia region by Vázquez-Roig et al. [35]. 
Chiral analysis also helped in understanding an unexpectedly 
high quantity of ecstasy detected during a monitoring cam-
paign in 2011 in Dutch cities. Indeed, it was confirmed that 
high levels of MDMA were identified as racemic via chiral 
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chromatography coupled with MS/MS, which indicated di-
rect disposal of unused MDMA possibly as a result of a po-
lice raid at a nearby illegal production facility [91].  
Recently developed by Castrignanò and Kasprzyk-
Hordern, [38] multi-residue chiral method enabled simulta-
neous analysis of 56 biomarkers including: amphetamine, 
methamphetamine, MDA, MDMA, MDEA, mephedrone, 4-
hydroxy-3-methoxyamphetamine (HMA), 4-hydroxy-3-
methoxymethamphetamine (HMMA), paramethoxyam-
phetamine (PMA), tramadol, venlafaxine, desvenlafaxine, 
ephedrines, fluoxetine and norfluoxetine (Fig. 4). This study 
allowed for the first time for enantiomeric profiling of 
mephedrone in wastewater. 
Fig. (4). LC-MS/MS chromatograms using a CBH column for (illicit) drugs of abuse and their metabolites spiked at 500 g L-1 into a influent 
wastewater sample and extracted by SPE (E1/D1 means first-eluted enantiomer/diastereisomer, E2/D2 means second-eluted enanti-
omer/diastereisomer). 
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5. CONCLUSION 
Many PACs are chiral. Unfortunately, the phenomenon 
of chirality, despite its great importance in the pharmaceuti-
cal industry, has been mostly ignored in the environmental 
field. Currently, environmental fate and toxicity of chiral 
drugs are assessed without taking into consideration their 
enantiomeric composition. This might lead to a significant 
under or overestimation of toxicity of chiral drugs and to 
incorrect ERA. Limited published research concerning fate 
of cPACs revealed that they are usually present in the envi-
ronment in non-racemic mixtures of enantiomers. Further-
more, many cPACs undergo stereoselective metabolism in 
humans and once excreted, they are subject to stereoselective 
microbial metabolism during wastewater treatment and in the 
environment. Limited research in this area is associated with 
lack of analytical methods allowing for enantiomeric profil-
ing of cPACs at trace ppt levels in complex environmental 
matrices. This review outlined recent advances in the field of 
environmental chiral analysis of cPACs as well its various 
applications. An increase in a number of papers published in 
the area of chiral environmental analysis indicates that re-
searchers are actively pursuing new opportunities to provide 
better understanding of environmental impacts resulting 
from the enantiomerism of cPACs. 
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